



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy

Phone 503-947-5220 | Fax 503-947-1119

## Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, August 4<sup>th</sup>, 2022 1:00 - 5:00 PM

Via Zoom webinar

### MEETING MINUTES

---

**NOTE:** Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

**Members Present:**; Stacy Ramirez, PharmD; Bill Origer, MD; Tim Langford, PharmD; Eddie Saito, PharmD; Russ Huffman, PMHNP; Mark Helm, MD; Cat Livingston, MD

**Staff Present:** Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Lan Starkweather, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Megan Herink, PharmD; Brandon Wells; Kyle Hamilton; Andrew Gibler, PharmD; Trevor Douglass, DC, MPH; Kathy Sentena, PharmD; Deborah Weston, JD

**Audience:** **Arlene Mejia, Pierre Fabre USA; Allison Small, OHSU;** Brady Hurtgen, Horizon Therapeutics; Brandie Feger, Advanced Health; Chris Ferrin, Samaritan Health Plans; Evie Knisely, Novartis; Gloria Zepeda, P4 Pharmacy AllCare; Kaitlyn Molina, Samaritan Health Plan; Lisa Rawlins; Lori McDermott, Viking HCS; Marc Rueckert, Argenx; Mark Kantor, AllCare CCO; Matt Worthy, OHSU; Michael Foster, BMS; Michele Sabados, Alkermes; Nana Ama Kuffour, IHN; **Phil Wettestad, Novartis;** Saghi Maleki, Takeda Pharmaceuticals; Sarah Lott, Artia Solutions; Shirley Quach; Tina Andrews, Umpqua Health Alliance; Tom Telly, Supernus; Trish Olson; Andrea Willcuts, Idorsia; YJ Shukla, EOCCO Moda Health

**(\*) Provided verbal testimony**

**Written testimony:** Posted to OSU Website

---

### I. CALL TO ORDER

A. Roll Call & Introductions

- Called to order at approx. 1:02 p.m., introductions by Committee and staff

- B. Conflict of Interest Declaration – no new conflicts of interest were declared
- C. Approval of Agenda and June 2022 Minutes presented by Roger Citron  
**ACTION: Motion to approve, 2<sup>nd</sup>, Drs. Langford and Saito abstained, all in favor**
- D. Department Update provided by Andrew Gibler, PharmD

---

## II. CONSENT AGENDA TOPICS

- A. **CMS Annual Report**
- B. **Review Standards and Methods for Evidence Assessment**
- C. **P&T Operating Procedures**
- D. **Quarterly Utilization Report**
  - **Public Comment**

---

## III. DUR ACTIVITIES

- A. **ProDUR Report:** Lan Starkweather, PharmD
- B. **RetroDUR Report:** Dave Engen, PharmD
- C. **Oregon State Drug Review:** Kathy Sentena, PharmD
  - **Second-Generation Antipsychotic Use in Children and Adolescents**
  - **Updated 2021 Treatment Guidelines for Sexually Transmitted Infections****ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

---

## IV. PREFERRED DRUG LIST NEW BUSINESS

- A. **Estrogen Class Update:** Kathy Sentena, PharmD  
**Recommendations:**
  - No PDL changes recommended based on review of recently published evidence
  - Evaluate costs in executive session**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**
  
- B. **PCSK9 Modulator Class Update with New Drug Evaluation:** Megan Herink, PharmD  
**Recommendations:**
  - Change the name of the class to “PCSK9 Modulators” and no PDL changes recommended based on review of recently published evidence
  - Maintain inclisiran as non-preferred on the PDL
  - Modify the PCSK9 Modulators PA criteria to limit inclisiran to its FDA indication and require trial of agents with evidence of CV risk reduction
  - Evaluate costs in executive session**Public Comment:** Phil Wettestad, Novartis

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**C. Oral Thyroid Hormones Class Update: Kathy Sentena, PharmD**

**Recommendations:**

- Add class to the PDL and designate at least one formulation of levothyroxine preferred
- Evaluate costs in executive session

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**D. Oral Beta Blocker Class Update: Deanna Moretz, PharmD**

**Recommendations:**

- Designate acebutolol non-preferred and at least one formulation of extended-release propranolol and propranolol oral solution preferred on the PDL
- Evaluate costs in executive session

**Public Comment:** Phil Wettestad, Novartis; Arlene Mejia, Pierre Fabre Group; Alison Small, OHSU

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**E. Nasal Allergy inhaler Class Update: Deanna Moretz, PharmD**

**Recommendations:**

- No PDL changes recommended based on review of recently published evidence
- Remove PA requirement for intranasal allergy products for children 20 years of age and younger who are eligible for EPSDT
- Evaluate costs in executive session

**ACTION:** The Committee amended the recommendation to limit to preferred agents and changed the wording from 20 and younger to “up to their 21<sup>st</sup> birthday”

**Motion to approve, 2<sup>nd</sup>, all in favor**

**F. Sedative Class Update and New Drug Evaluation: Sarah Servid, PharmD**

**Recommendations:**

- No PDL changes recommended based on review of recently published evidence
- Update the PA criteria to facilitate benzodiazepine tapers as described in recent guidance from the Mental Health Clinical Advisory Group (MHCAG)
- Evaluate costs in executive session

**Motion to approve, 2<sup>nd</sup>, all in favor**

---

**V. EXECUTIVE SESSION**

**Members Present:** Stacy Ramirez, PharmD; Bill Origer, MD; Tim Langford, PharmD; Eddie Saito, PharmD; Russ Huffman, PMHNP; Mark Helm, MD; Cat Livingston, MD

**Staff Present:** Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Lan Starkweather, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Megan Herink, PharmD; Brandon Wells; Kyle Hamilton; Andrew Gibler, PharmD; Trevor Douglass, DC, MPH; Kathy Sentena, PharmD; Deborah Weston, JD

---

## VI. RECONVENE for PUBLIC RECOMMENDATIONS

### A. Estrogen Class Update

**Recommendation:** Make: oral Prempro, Premarin, Premphase and Angeliq; topical Elestrin; and vaginal Femring, Estring, estradiol cream and Estrace preferred on the PDL

**ACTION:** Motion to approve, 2<sup>nd</sup>, all in favor

### B. PCSK9 Modulator Class Update with NDE

**Recommendation:** No changes to the PDL are recommended

**ACTION:** Motion to approve, 2<sup>nd</sup>, all in favor

### C. Oral Thyroid Hormones Class Update:

**Recommendation:** Make levothyroxine preferred and all other agents non-preferred and grandfather patients on non-preferred agents for 12 months

**ACTION:** Motion to approve, 2<sup>nd</sup>, majority in favor with one opposed

### D. Oral Beta Blocker Class Update

**Recommendation:** Make propranolol SA 24 hour capsules, generic oral propranolol solution, and nadolol tabs preferred on the PDL and Hemangeol open access up to 6 months old

**ACTION:** Motion to approve, 2<sup>nd</sup>, all in favor

### E. Nasal Allergy Inhaler Class Update

**Recommendation:** No changes to the PDL are recommended

**ACTION:** Motion to approve, 2<sup>nd</sup>, all in favor

### F. PCSK9 Modulator Class Update with NDE

**Recommendation:** No changes to the PDL are recommended

**ACTION:** Motion to approve, 2<sup>nd</sup>, all in favor

---

## VII. ADJOURN